HealthNews

Curebase Adds Two Clinical Trial Veterans To Kick-off New Advisory Board

Spread the love

Curebase Adds

Curebase, a company committed to democratizing access to clinical studies, has named Dr. Aaron Kamauu and Dr. Amir Lahav to the Curebase Advisory Board. The new board members will help the company develop technology, data, partnership and growth strategies designed to increase its share of the global decentralized clinical trial (DCT) market.

Recommended Articles:-https://prgazette.com/news/symplr-completes/

Platforms, Not Government, Can Save Clinical Trials

Curebase’s diversified model enables the inclusion of underrepresented patient populations otherwise excluded from clinical trials. The company’s virtual research sites also offer patients a unique opportunity to participate in clinical studies, regardless of their location. The Curebase platform empowers sponsors, CROs and physicians from practices of all sizes to conduct clinical research more efficiently, including private practices, independent clinics, and large academic research sites.

An industry-leading advisor in the Real-World Data (RWD) space, Dr. Kamauu is managing director of Ikaika Health, which provides consulting services focusing on leveraging RWD to support a variety of clinical research, informatics, clinical trials, and drug development activities. Prior to joining Ikaika, he served as vice president of real-world data services for Parexel and was founder and CEO of Anolinx, a healthcare data and biomedical informatics startup.

Dr. Kamauu has a medical degree from the University of Utah School of Medicine and master’s degrees in public health and biomedical informatics from the University of Utah. Dr. Kamauu is a member of leading medical societies where he has presented innovative research in clinical research informatics, public health informatics, and radiology/imaging informatics.

“Decentralized clinical trials have achieved a level of acceptance and now we’re at the point of iteration and evolution,” Dr. Kamauu said. “Curebase is doing great work at this. In particular, the Curebase platform is robust and flexible, avoiding becoming locked into a large infrastructure that might be robust, yet not very flexible. I look forward to working with Curebase to expand how they leverage and generate RWD in support of clinical research.”

Dr. Lahav is the head of strategic R&D for digital healthcare innovation at Mitsubishi Tanabe Pharma Holdings America and an industry-leading innovator in artificial intelligence/machine learning digital biomarker development for neurodegenerative diseases. He also currently serves as chief of digital health and strategy at Redenlab. His previous professional positions include executive director and head of digital medicine at Karyopharm Therapeutics and digital health and clinical innovation lead for rare diseases at Pfizer.

Worldwide Clinical Trials teams with Science 37 to advance remote trial  offerings | FierceBiotech

He earned a Doctor of Science degree in health and rehabilitation services from Boston University and completed a postdoctoral fellowship in neurology from Harvard Medical School, where he has served as an assistant professor of pediatrics.

“Smartphones have become an integral part of our lives and can be used through apps to collect valuable patient data,” said Dr. Lahav. “Curebase has built a sophisticated and scalable platform that takes advantage of digital technologies in a very elegant way. I’m excited to work with the company as it continues to build out its DCT capabilities.”

Recommended Articles:-https://prgazette.com/news/visionflex-chooses/

“Dr. Lahav and Dr. Kamauu are two of the most innovative and forward thinkers in healthcare,” said Curebase CEO Tom Lemberg. “Their experience and insights will be invaluable to further development of our platform and business strategy.”


Spread the love

Craig Hill

Craig began writing for prgazette.com in 2005, resulting in engaging and fascinating editorials about science and wellness progress. Craig’s inspirational and accurate science and health articles have made her very popular with the viewers. Craig graduated at the University of Illinois at Urbana-Champaign with a Bachelor of Arts degree at October in 2004. He then completed a science college internship in Fermilab, followed using a communications internship in Caterpillar. Ever since that moment, he has been writing in an independent capability for several science, health, technology, along with other books.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button